King joined San Francisco–based iRhythm’s board in July 2012 and served as the company’s president and CEO from then until January 2021.
“On behalf of the entire iRhythm team, I would like to thank Kevin for his contributions over the last several years,” iRhythm President and CEO Quentin Blackford said in a news release. “iRhythm would not be the company that it is today without Kevin’s leadership and we thank him for the many achievements during his tenure. I am personally grateful to Kevin for him welcoming me into the company and ensuring a smooth transition.”
King led the company, which develops the Zio XT ambulatory cardiac monitor, a wearable ECG device meant to be smaller and more comfortable than a traditional Holter monitor while still offering accuracy in cardiac monitoring, until former Medtronic executive Mike Coyle took over as CEO last year. Coyle then stepped down for personal reasons in June 2021, which led to the appointment of Blackford, formerly COO at Dexcom, to the role.
“In my 10 years with the company, iRhythm has grown into a market-leading company that has changed the standard of care in cardiac monitoring. We have served over four million patients and I am extremely proud of all that we have accomplished,” King said. “It has been an amazing journey and I am looking forward to watching the company’s continued success under Quentin’s leadership.”